← All trials
NCT01443065
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2011
- Primary completion
- Mar 1, 2014
- Completion date
- Jan 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- UNICANCERLead sponsor
- Centre Leon BerardOverall official - principal investigator
- Institut Paoli-CalmettesOverall official - principal investigator
- University of LilleOverall official - principal investigator
- Institut de Cancerologie de l'Ouest Paul PapinOverall official - principal investigator
- University of AngersOverall official - principal investigator
- University of LyonOverall official - principal investigator
- CHU BesançonOverall official - principal investigator
- CHU MorvanOverall official - principal investigator
- CHR AnnecyOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- Centre Georges Francois LeclercOverall official - principal investigator
- Centre Hospitalier La Source, OrleansOverall official - principal investigator
- University of Caen-NormandieOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- Groupe Hospitalier Paris Saint JosephOverall official - principal investigator
- Curie InstituteOverall official - principal investigator
- Institut Gustave RoussyOverall official - principal investigator
- University of BordeauxOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.